Načítá se...
DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure
Heart failure (HF) continues to be a major global health problem with a notable impact in terms of morbidity and mortality and so, in consequence, with a large unmet necessity for new therapies. The inhibition of sodium–glucose cotransporter 2 (SGLT2) causes glycosuria and natriuresis, leading to re...
Uloženo v:
| Vydáno v: | Drugs Context |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioExcel Publishing Ltd
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7051244/ https://ncbi.nlm.nih.gov/pubmed/32165892 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.2019-11-3 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|